Pharma & Healthcare
Global VEGF Inhibitors for Cancer Market Research Report 2026
- Feb 24, 26
- ID: 720757
- Pages: 124
- Figures: 121
- Views: 1
This report delivers a comprehensive overview of the global VEGF Inhibitors for Cancer market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding VEGF Inhibitors for Cancer. The VEGF Inhibitors for Cancer market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global VEGF Inhibitors for Cancer market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist VEGF Inhibitors for Cancer manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Sanofi
Roche
Eli Lilly
Pfizer
Celltrion Healthcare
Amgen
Amneal Pharmaceuticals
Chia Tai Tianqing
Qilu Pharma
Boan Biotech
Jiangsu Hengrui Pharmaceuticals
SinoCellTech
Innovent
Segment by Type
Ramucirumab
Aflibercept
Ramucirumab
Other
by Application
Metastatic colorectal cancer
Metastatic Non-small Cell Lung Cancer
Recurrent Glioblastoma
Cervical Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for VEGF Inhibitors for Cancer manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines VEGF Inhibitors for Cancer sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global VEGF Inhibitors for Cancer market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist VEGF Inhibitors for Cancer manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Sanofi
Roche
Eli Lilly
Pfizer
Celltrion Healthcare
Amgen
Amneal Pharmaceuticals
Chia Tai Tianqing
Qilu Pharma
Boan Biotech
Jiangsu Hengrui Pharmaceuticals
SinoCellTech
Innovent
Segment by Type
Ramucirumab
Aflibercept
Ramucirumab
Other
by Application
Metastatic colorectal cancer
Metastatic Non-small Cell Lung Cancer
Recurrent Glioblastoma
Cervical Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for VEGF Inhibitors for Cancer manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines VEGF Inhibitors for Cancer sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 VEGF Inhibitors for Cancer Market Overview
1.1 Product Definition
1.2 VEGF Inhibitors for Cancer by Type
1.2.1 Global VEGF Inhibitors for Cancer Market Value by Type: 2025 vs 2032
1.2.2 Ramucirumab
1.2.3 Aflibercept
1.2.4 Ramucirumab
1.2.5 Other
1.3 VEGF Inhibitors for Cancer by Application
1.3.1 Global VEGF Inhibitors for Cancer Market Value by Application: 2025 vs 2032
1.3.2 Metastatic colorectal cancer
1.3.3 Metastatic Non-small Cell Lung Cancer
1.3.4 Recurrent Glioblastoma
1.3.5 Cervical Cancer
1.3.6 Other
1.4 Global VEGF Inhibitors for Cancer Market Size Estimates and Forecasts
1.4.1 Global VEGF Inhibitors for Cancer Revenue 2021–2032
1.4.2 Global VEGF Inhibitors for Cancer Sales 2021–2032
1.4.3 Global VEGF Inhibitors for Cancer Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 VEGF Inhibitors for Cancer Market Competition by Manufacturers
2.1 Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021–2026)
2.2 Global VEGF Inhibitors for Cancer Revenue Market Share by Manufacturers (2021–2026)
2.3 Global VEGF Inhibitors for Cancer Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of VEGF Inhibitors for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of VEGF Inhibitors for Cancer, Product Types and Applications
2.7 Global Key Manufacturers of VEGF Inhibitors for Cancer, Date of Entry into the Industry
2.8 Global VEGF Inhibitors for Cancer Market Competitive Situation and Trends
2.8.1 Global VEGF Inhibitors for Cancer Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global VEGF Inhibitors for Cancer Players Market Share by Revenue
2.8.3 Global VEGF Inhibitors for Cancer Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global VEGF Inhibitors for Cancer Market Scenario by Region
3.1 Global VEGF Inhibitors for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global VEGF Inhibitors for Cancer Sales by Region: 2021–2032
3.2.1 Global VEGF Inhibitors for Cancer Sales by Region: 2021–2026
3.2.2 Global VEGF Inhibitors for Cancer Sales by Region: 2027–2032
3.3 Global VEGF Inhibitors for Cancer Revenue by Region: 2021–2032
3.3.1 Global VEGF Inhibitors for Cancer Revenue by Region: 2021–2026
3.3.2 Global VEGF Inhibitors for Cancer Revenue by Region: 2027–2032
3.4 North America VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.4.1 North America VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.4.3 North America VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.5.1 Europe VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.5.3 Europe VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VEGF Inhibitors for Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific VEGF Inhibitors for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific VEGF Inhibitors for Cancer Sales by Region (2021–2032)
3.6.3 Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.7.1 Latin America VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.7.3 Latin America VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.8.3 Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VEGF Inhibitors for Cancer Sales by Type (2021–2032)
4.1.1 Global VEGF Inhibitors for Cancer Sales by Type (2021–2026)
4.1.2 Global VEGF Inhibitors for Cancer Sales by Type (2027–2032)
4.1.3 Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021–2032)
4.2 Global VEGF Inhibitors for Cancer Revenue by Type (2021–2032)
4.2.1 Global VEGF Inhibitors for Cancer Revenue by Type (2021–2026)
4.2.2 Global VEGF Inhibitors for Cancer Revenue by Type (2027–2032)
4.2.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021–2032)
4.3 Global VEGF Inhibitors for Cancer Price by Type (2021–2032)
5 Segment by Application
5.1 Global VEGF Inhibitors for Cancer Sales by Application (2021–2032)
5.1.1 Global VEGF Inhibitors for Cancer Sales by Application (2021–2026)
5.1.2 Global VEGF Inhibitors for Cancer Sales by Application (2027–2032)
5.1.3 Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021–2032)
5.2 Global VEGF Inhibitors for Cancer Revenue by Application (2021–2032)
5.2.1 Global VEGF Inhibitors for Cancer Revenue by Application (2021–2026)
5.2.2 Global VEGF Inhibitors for Cancer Revenue by Application (2027–2032)
5.2.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021–2032)
5.3 Global VEGF Inhibitors for Cancer Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Sanofi VEGF Inhibitors for Cancer Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Roche VEGF Inhibitors for Cancer Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Eli Lilly VEGF Inhibitors for Cancer Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer VEGF Inhibitors for Cancer Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Celltrion Healthcare
6.5.1 Celltrion Healthcare Company Information
6.5.2 Celltrion Healthcare Description and Business Overview
6.5.3 Celltrion Healthcare VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio
6.5.5 Celltrion Healthcare Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Company Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Amgen VEGF Inhibitors for Cancer Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Amneal Pharmaceuticals
6.7.1 Amneal Pharmaceuticals Company Information
6.7.2 Amneal Pharmaceuticals Description and Business Overview
6.7.3 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
6.7.5 Amneal Pharmaceuticals Recent Developments/Updates
6.8 Chia Tai Tianqing
6.8.1 Chia Tai Tianqing Company Information
6.8.2 Chia Tai Tianqing Description and Business Overview
6.8.3 Chia Tai Tianqing VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio
6.8.5 Chia Tai Tianqing Recent Developments/Updates
6.9 Qilu Pharma
6.9.1 Qilu Pharma Company Information
6.9.2 Qilu Pharma Description and Business Overview
6.9.3 Qilu Pharma VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio
6.9.5 Qilu Pharma Recent Developments/Updates
6.10 Boan Biotech
6.10.1 Boan Biotech Company Information
6.10.2 Boan Biotech Description and Business Overview
6.10.3 Boan Biotech VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Boan Biotech VEGF Inhibitors for Cancer Product Portfolio
6.10.5 Boan Biotech Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 SinoCellTech
6.12.1 SinoCellTech Company Information
6.12.2 SinoCellTech Description and Business Overview
6.12.3 SinoCellTech VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 SinoCellTech VEGF Inhibitors for Cancer Product Portfolio
6.12.5 SinoCellTech Recent Developments/Updates
6.13 Innovent
6.13.1 Innovent Company Information
6.13.2 Innovent Description and Business Overview
6.13.3 Innovent VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Innovent VEGF Inhibitors for Cancer Product Portfolio
6.13.5 Innovent Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VEGF Inhibitors for Cancer Industry Chain Analysis
7.2 VEGF Inhibitors for Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VEGF Inhibitors for Cancer Production Mode & Process Analysis
7.4 VEGF Inhibitors for Cancer Sales and Marketing
7.4.1 VEGF Inhibitors for Cancer Sales Channels
7.4.2 VEGF Inhibitors for Cancer Distributors
7.5 VEGF Inhibitors for Cancer Customer Analysis
8 VEGF Inhibitors for Cancer Market Dynamics
8.1 VEGF Inhibitors for Cancer Industry Trends
8.2 VEGF Inhibitors for Cancer Market Drivers
8.3 VEGF Inhibitors for Cancer Market Challenges
8.4 VEGF Inhibitors for Cancer Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 VEGF Inhibitors for Cancer by Type
1.2.1 Global VEGF Inhibitors for Cancer Market Value by Type: 2025 vs 2032
1.2.2 Ramucirumab
1.2.3 Aflibercept
1.2.4 Ramucirumab
1.2.5 Other
1.3 VEGF Inhibitors for Cancer by Application
1.3.1 Global VEGF Inhibitors for Cancer Market Value by Application: 2025 vs 2032
1.3.2 Metastatic colorectal cancer
1.3.3 Metastatic Non-small Cell Lung Cancer
1.3.4 Recurrent Glioblastoma
1.3.5 Cervical Cancer
1.3.6 Other
1.4 Global VEGF Inhibitors for Cancer Market Size Estimates and Forecasts
1.4.1 Global VEGF Inhibitors for Cancer Revenue 2021–2032
1.4.2 Global VEGF Inhibitors for Cancer Sales 2021–2032
1.4.3 Global VEGF Inhibitors for Cancer Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 VEGF Inhibitors for Cancer Market Competition by Manufacturers
2.1 Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021–2026)
2.2 Global VEGF Inhibitors for Cancer Revenue Market Share by Manufacturers (2021–2026)
2.3 Global VEGF Inhibitors for Cancer Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of VEGF Inhibitors for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of VEGF Inhibitors for Cancer, Product Types and Applications
2.7 Global Key Manufacturers of VEGF Inhibitors for Cancer, Date of Entry into the Industry
2.8 Global VEGF Inhibitors for Cancer Market Competitive Situation and Trends
2.8.1 Global VEGF Inhibitors for Cancer Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global VEGF Inhibitors for Cancer Players Market Share by Revenue
2.8.3 Global VEGF Inhibitors for Cancer Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global VEGF Inhibitors for Cancer Market Scenario by Region
3.1 Global VEGF Inhibitors for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global VEGF Inhibitors for Cancer Sales by Region: 2021–2032
3.2.1 Global VEGF Inhibitors for Cancer Sales by Region: 2021–2026
3.2.2 Global VEGF Inhibitors for Cancer Sales by Region: 2027–2032
3.3 Global VEGF Inhibitors for Cancer Revenue by Region: 2021–2032
3.3.1 Global VEGF Inhibitors for Cancer Revenue by Region: 2021–2026
3.3.2 Global VEGF Inhibitors for Cancer Revenue by Region: 2027–2032
3.4 North America VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.4.1 North America VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.4.3 North America VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.5.1 Europe VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.5.3 Europe VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VEGF Inhibitors for Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific VEGF Inhibitors for Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific VEGF Inhibitors for Cancer Sales by Region (2021–2032)
3.6.3 Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.7.1 Latin America VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.7.3 Latin America VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa VEGF Inhibitors for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa VEGF Inhibitors for Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (2021–2032)
3.8.3 Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VEGF Inhibitors for Cancer Sales by Type (2021–2032)
4.1.1 Global VEGF Inhibitors for Cancer Sales by Type (2021–2026)
4.1.2 Global VEGF Inhibitors for Cancer Sales by Type (2027–2032)
4.1.3 Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021–2032)
4.2 Global VEGF Inhibitors for Cancer Revenue by Type (2021–2032)
4.2.1 Global VEGF Inhibitors for Cancer Revenue by Type (2021–2026)
4.2.2 Global VEGF Inhibitors for Cancer Revenue by Type (2027–2032)
4.2.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021–2032)
4.3 Global VEGF Inhibitors for Cancer Price by Type (2021–2032)
5 Segment by Application
5.1 Global VEGF Inhibitors for Cancer Sales by Application (2021–2032)
5.1.1 Global VEGF Inhibitors for Cancer Sales by Application (2021–2026)
5.1.2 Global VEGF Inhibitors for Cancer Sales by Application (2027–2032)
5.1.3 Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021–2032)
5.2 Global VEGF Inhibitors for Cancer Revenue by Application (2021–2032)
5.2.1 Global VEGF Inhibitors for Cancer Revenue by Application (2021–2026)
5.2.2 Global VEGF Inhibitors for Cancer Revenue by Application (2027–2032)
5.2.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021–2032)
5.3 Global VEGF Inhibitors for Cancer Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Sanofi VEGF Inhibitors for Cancer Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Roche VEGF Inhibitors for Cancer Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Eli Lilly VEGF Inhibitors for Cancer Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer VEGF Inhibitors for Cancer Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Celltrion Healthcare
6.5.1 Celltrion Healthcare Company Information
6.5.2 Celltrion Healthcare Description and Business Overview
6.5.3 Celltrion Healthcare VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio
6.5.5 Celltrion Healthcare Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Company Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Amgen VEGF Inhibitors for Cancer Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Amneal Pharmaceuticals
6.7.1 Amneal Pharmaceuticals Company Information
6.7.2 Amneal Pharmaceuticals Description and Business Overview
6.7.3 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
6.7.5 Amneal Pharmaceuticals Recent Developments/Updates
6.8 Chia Tai Tianqing
6.8.1 Chia Tai Tianqing Company Information
6.8.2 Chia Tai Tianqing Description and Business Overview
6.8.3 Chia Tai Tianqing VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio
6.8.5 Chia Tai Tianqing Recent Developments/Updates
6.9 Qilu Pharma
6.9.1 Qilu Pharma Company Information
6.9.2 Qilu Pharma Description and Business Overview
6.9.3 Qilu Pharma VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio
6.9.5 Qilu Pharma Recent Developments/Updates
6.10 Boan Biotech
6.10.1 Boan Biotech Company Information
6.10.2 Boan Biotech Description and Business Overview
6.10.3 Boan Biotech VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Boan Biotech VEGF Inhibitors for Cancer Product Portfolio
6.10.5 Boan Biotech Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 SinoCellTech
6.12.1 SinoCellTech Company Information
6.12.2 SinoCellTech Description and Business Overview
6.12.3 SinoCellTech VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 SinoCellTech VEGF Inhibitors for Cancer Product Portfolio
6.12.5 SinoCellTech Recent Developments/Updates
6.13 Innovent
6.13.1 Innovent Company Information
6.13.2 Innovent Description and Business Overview
6.13.3 Innovent VEGF Inhibitors for Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Innovent VEGF Inhibitors for Cancer Product Portfolio
6.13.5 Innovent Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VEGF Inhibitors for Cancer Industry Chain Analysis
7.2 VEGF Inhibitors for Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VEGF Inhibitors for Cancer Production Mode & Process Analysis
7.4 VEGF Inhibitors for Cancer Sales and Marketing
7.4.1 VEGF Inhibitors for Cancer Sales Channels
7.4.2 VEGF Inhibitors for Cancer Distributors
7.5 VEGF Inhibitors for Cancer Customer Analysis
8 VEGF Inhibitors for Cancer Market Dynamics
8.1 VEGF Inhibitors for Cancer Industry Trends
8.2 VEGF Inhibitors for Cancer Market Drivers
8.3 VEGF Inhibitors for Cancer Market Challenges
8.4 VEGF Inhibitors for Cancer Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global VEGF Inhibitors for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global VEGF Inhibitors for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global VEGF Inhibitors for Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global VEGF Inhibitors for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market VEGF Inhibitors for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of VEGF Inhibitors for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of VEGF Inhibitors for Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of VEGF Inhibitors for Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VEGF Inhibitors for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on VEGF Inhibitors for Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global VEGF Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 18. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021–2026)
Table 19. Global VEGF Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 20. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2027–2032)
Table 21. Global VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 27. North America VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 28. North America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific VEGF Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific VEGF Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global VEGF Inhibitors for Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global VEGF Inhibitors for Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021–2026)
Table 53. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2027–2032)
Table 54. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021–2026)
Table 59. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2027–2032)
Table 60. Global VEGF Inhibitors for Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global VEGF Inhibitors for Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021–2026)
Table 63. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2027–2032)
Table 64. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021–2026)
Table 69. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2027–2032)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Sanofi VEGF Inhibitors for Cancer Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Roche VEGF Inhibitors for Cancer Product
Table 79. Roche Recent Developments/Updates
Table 80. Eli Lilly Company Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eli Lilly VEGF Inhibitors for Cancer Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer VEGF Inhibitors for Cancer Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Celltrion Healthcare Company Information
Table 91. Celltrion Healthcare Description and Business Overview
Table 92. Celltrion Healthcare VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Celltrion Healthcare VEGF Inhibitors for Cancer Product
Table 94. Celltrion Healthcare Recent Developments/Updates
Table 95. Amgen Company Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Amgen VEGF Inhibitors for Cancer Product
Table 99. Amgen Recent Developments/Updates
Table 100. Amneal Pharmaceuticals Company Information
Table 101. Amneal Pharmaceuticals Description and Business Overview
Table 102. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product
Table 104. Amneal Pharmaceuticals Recent Developments/Updates
Table 105. Chia Tai Tianqing Company Information
Table 106. Chia Tai Tianqing Description and Business Overview
Table 107. Chia Tai Tianqing VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Chia Tai Tianqing VEGF Inhibitors for Cancer Product
Table 109. Chia Tai Tianqing Recent Developments/Updates
Table 110. Qilu Pharma Company Information
Table 111. Qilu Pharma Description and Business Overview
Table 112. Qilu Pharma VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Qilu Pharma VEGF Inhibitors for Cancer Product
Table 114. Qilu Pharma Recent Developments/Updates
Table 115. Boan Biotech Company Information
Table 116. Boan Biotech Description and Business Overview
Table 117. Boan Biotech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Boan Biotech VEGF Inhibitors for Cancer Product
Table 119. Boan Biotech Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. SinoCellTech Company Information
Table 126. SinoCellTech Description and Business Overview
Table 127. SinoCellTech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. SinoCellTech VEGF Inhibitors for Cancer Product
Table 129. SinoCellTech Recent Developments/Updates
Table 130. Innovent Company Information
Table 131. Innovent Description and Business Overview
Table 132. Innovent VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Innovent VEGF Inhibitors for Cancer Product
Table 134. Innovent Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. VEGF Inhibitors for Cancer Distributors List
Table 138. VEGF Inhibitors for Cancer Customers List
Table 139. VEGF Inhibitors for Cancer Market Trends
Table 140. VEGF Inhibitors for Cancer Market Drivers
Table 141. VEGF Inhibitors for Cancer Market Challenges
Table 142. VEGF Inhibitors for Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of VEGF Inhibitors for Cancer
Figure 2. Global VEGF Inhibitors for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global VEGF Inhibitors for Cancer Market Share by Type: 2025 & 2032
Figure 4. Ramucirumab Product Picture
Figure 5. Aflibercept Product Picture
Figure 6. Ramucirumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global VEGF Inhibitors for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 9. Global VEGF Inhibitors for Cancer Market Share by Application: 2025 & 2032
Figure 10. Metastatic colorectal cancer
Figure 11. Metastatic Non-small Cell Lung Cancer
Figure 12. Recurrent Glioblastoma
Figure 13. Cervical Cancer
Figure 14. Other
Figure 15. Global VEGF Inhibitors for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global VEGF Inhibitors for Cancer Market Size (US$ Million), 2021–2032
Figure 17. Global VEGF Inhibitors for Cancer Sales (K Units), 2021–2032
Figure 18. Global VEGF Inhibitors for Cancer Average Price (US$/Unit), 2021–2032
Figure 19. VEGF Inhibitors for Cancer Report Years Considered
Figure 20. VEGF Inhibitors for Cancer Sales Share by Manufacturers in 2025
Figure 21. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global VEGF Inhibitors for Cancer Players: Market Share by Revenue in VEGF Inhibitors for Cancer in 2025
Figure 23. VEGF Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 26. North America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 27. United States VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 30. Europe VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 31. Germany VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific VEGF Inhibitors for Cancer Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific VEGF Inhibitors for Cancer Revenue Market Share by Region (2021–2032)
Figure 38. China VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 46. Latin America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 47. Mexico VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 53. Turkey VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of VEGF Inhibitors for Cancer by Type (2021–2032)
Figure 57. Global Revenue Market Share of VEGF Inhibitors for Cancer by Type (2021–2032)
Figure 58. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of VEGF Inhibitors for Cancer by Application (2021–2032)
Figure 60. Global Revenue Market Share of VEGF Inhibitors for Cancer by Application (2021–2032)
Figure 61. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 62. VEGF Inhibitors for Cancer Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global VEGF Inhibitors for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global VEGF Inhibitors for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global VEGF Inhibitors for Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global VEGF Inhibitors for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market VEGF Inhibitors for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of VEGF Inhibitors for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of VEGF Inhibitors for Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of VEGF Inhibitors for Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of VEGF Inhibitors for Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VEGF Inhibitors for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on VEGF Inhibitors for Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global VEGF Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 18. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021–2026)
Table 19. Global VEGF Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 20. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2027–2032)
Table 21. Global VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 27. North America VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 28. North America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific VEGF Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific VEGF Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific VEGF Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa VEGF Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa VEGF Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global VEGF Inhibitors for Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global VEGF Inhibitors for Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021–2026)
Table 53. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2027–2032)
Table 54. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021–2026)
Table 59. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2027–2032)
Table 60. Global VEGF Inhibitors for Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global VEGF Inhibitors for Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021–2026)
Table 63. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2027–2032)
Table 64. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global VEGF Inhibitors for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021–2026)
Table 69. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2027–2032)
Table 70. Sanofi Company Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Sanofi VEGF Inhibitors for Cancer Product
Table 74. Sanofi Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Roche VEGF Inhibitors for Cancer Product
Table 79. Roche Recent Developments/Updates
Table 80. Eli Lilly Company Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eli Lilly VEGF Inhibitors for Cancer Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer VEGF Inhibitors for Cancer Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Celltrion Healthcare Company Information
Table 91. Celltrion Healthcare Description and Business Overview
Table 92. Celltrion Healthcare VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Celltrion Healthcare VEGF Inhibitors for Cancer Product
Table 94. Celltrion Healthcare Recent Developments/Updates
Table 95. Amgen Company Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Amgen VEGF Inhibitors for Cancer Product
Table 99. Amgen Recent Developments/Updates
Table 100. Amneal Pharmaceuticals Company Information
Table 101. Amneal Pharmaceuticals Description and Business Overview
Table 102. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product
Table 104. Amneal Pharmaceuticals Recent Developments/Updates
Table 105. Chia Tai Tianqing Company Information
Table 106. Chia Tai Tianqing Description and Business Overview
Table 107. Chia Tai Tianqing VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Chia Tai Tianqing VEGF Inhibitors for Cancer Product
Table 109. Chia Tai Tianqing Recent Developments/Updates
Table 110. Qilu Pharma Company Information
Table 111. Qilu Pharma Description and Business Overview
Table 112. Qilu Pharma VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Qilu Pharma VEGF Inhibitors for Cancer Product
Table 114. Qilu Pharma Recent Developments/Updates
Table 115. Boan Biotech Company Information
Table 116. Boan Biotech Description and Business Overview
Table 117. Boan Biotech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Boan Biotech VEGF Inhibitors for Cancer Product
Table 119. Boan Biotech Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. SinoCellTech Company Information
Table 126. SinoCellTech Description and Business Overview
Table 127. SinoCellTech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. SinoCellTech VEGF Inhibitors for Cancer Product
Table 129. SinoCellTech Recent Developments/Updates
Table 130. Innovent Company Information
Table 131. Innovent Description and Business Overview
Table 132. Innovent VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Innovent VEGF Inhibitors for Cancer Product
Table 134. Innovent Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. VEGF Inhibitors for Cancer Distributors List
Table 138. VEGF Inhibitors for Cancer Customers List
Table 139. VEGF Inhibitors for Cancer Market Trends
Table 140. VEGF Inhibitors for Cancer Market Drivers
Table 141. VEGF Inhibitors for Cancer Market Challenges
Table 142. VEGF Inhibitors for Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of VEGF Inhibitors for Cancer
Figure 2. Global VEGF Inhibitors for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global VEGF Inhibitors for Cancer Market Share by Type: 2025 & 2032
Figure 4. Ramucirumab Product Picture
Figure 5. Aflibercept Product Picture
Figure 6. Ramucirumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global VEGF Inhibitors for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 9. Global VEGF Inhibitors for Cancer Market Share by Application: 2025 & 2032
Figure 10. Metastatic colorectal cancer
Figure 11. Metastatic Non-small Cell Lung Cancer
Figure 12. Recurrent Glioblastoma
Figure 13. Cervical Cancer
Figure 14. Other
Figure 15. Global VEGF Inhibitors for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global VEGF Inhibitors for Cancer Market Size (US$ Million), 2021–2032
Figure 17. Global VEGF Inhibitors for Cancer Sales (K Units), 2021–2032
Figure 18. Global VEGF Inhibitors for Cancer Average Price (US$/Unit), 2021–2032
Figure 19. VEGF Inhibitors for Cancer Report Years Considered
Figure 20. VEGF Inhibitors for Cancer Sales Share by Manufacturers in 2025
Figure 21. Global VEGF Inhibitors for Cancer Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global VEGF Inhibitors for Cancer Players: Market Share by Revenue in VEGF Inhibitors for Cancer in 2025
Figure 23. VEGF Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global VEGF Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 26. North America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 27. United States VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 30. Europe VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 31. Germany VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific VEGF Inhibitors for Cancer Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific VEGF Inhibitors for Cancer Revenue Market Share by Region (2021–2032)
Figure 38. China VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 46. Latin America VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 47. Mexico VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa VEGF Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa VEGF Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 53. Turkey VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE VEGF Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of VEGF Inhibitors for Cancer by Type (2021–2032)
Figure 57. Global Revenue Market Share of VEGF Inhibitors for Cancer by Type (2021–2032)
Figure 58. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of VEGF Inhibitors for Cancer by Application (2021–2032)
Figure 60. Global Revenue Market Share of VEGF Inhibitors for Cancer by Application (2021–2032)
Figure 61. Global VEGF Inhibitors for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 62. VEGF Inhibitors for Cancer Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232